Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Rejects Revolade For Bleeding Disorders; GSK Considering Its Options

This article was originally published in The Pink Sheet Daily

Executive Summary

UK's cost effectiveness watchdog is uncertain about Revolade's long-term effects and cost
Advertisement

Related Content

Price Discount Paves The Way For NICE To Clear GSK’s Revolade
With Discount In Place, NICE Gives Nod To Amgen's Nplate For Bleeding Disorder
With Discount In Place, NICE Gives Nod To Amgen's Nplate For Bleeding Disorder
Japan Market Approval On Track For All-Case Surveillance Drugs From Lilly, GSK, Otsuka
GSK’s Promacta And Amgen’s Nplate Face Off In ITP Market
GSK’s Promacta And Amgen’s Nplate Face Off In ITP Market

Topics

Advertisement
UsernamePublicRestriction

Register

PS071170

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel